Media

Thetford Mines, Quebec – May 5, 2026 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the voting results of the annual general meeting of shareholders (the “Meeting”) held on April 29, 2026, in Quebec.

Thetford Mines, Quebec – April 9, 2026 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the appointment of Mr. Martin Kirouac as Chief Technology Officer of Groupe Technologique KDA Inc. (“GTK”), a wholly-owned subsidiary of KDA. This appointment is effective immediately.

Thetford Mines, Quebec – March 24, 2026 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, announces the closing of the transaction pursuant to which the Corporation acquired the twenty percent (20%) minority interest in the issued and outstanding shares of its subsidiary Groupe Technologique KDA Inc. (“GTK”) held by ERxpert Inc. (“ERxpert”) in exchange for thirty-five million (35,000,000) common shares of KDA’s share capital issued to ERxpert (the “Transaction”).

Thetford Mines, Quebec – March 2, 2026 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, announces the appointment of Mr. Jean-Marc Léveillé as President and interim Chief Executive Officer and Chairman of the Board of Directors of KDA and director and President of its subsidiary Groupe Technologique KDA Inc. (“GTK”), effective February 27, 2026.

Thetford Mines, Quebec – December 22, 2025 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to support the utility of next-generation sequencing (“NGS”) diagnostic testing for patients with metastatic breast cancer at Hôpital du Saint-Sacrement (CHU de Québec – Université Laval). NGS enables parallel analysis of multiple tumor genes to identify clinically actionable biomarkers and support faster, more informed treatment decisions.